Development of Assays for Detecting Significant Prostate Cancer Based on Molecular Alterations Associated with Cancer in Non-Neoplastic Prostate Tissue
Abstract
The goal of this project is to develop biopsy based assays to assess the probability that patients with a negative biopsy or with a prostate cancer (CaP) Gleason score 6 (GS6) biopsy actually have significant CaP of Gleason score 7 or higher which was missed during the biopsy evaluations due to insufficient sampling. Based on the concepts of the CaP field effect , this goal will be achieved by gene expression and epigenetic analysis of preneoplastic lesions and non-cancerous areas of prostate tissues from patients with CaP and benign prostate tissues from patients free of CaP. According to the DOD regulations, all research activities began after the approval of the research protocol by the HRPO in March 20 2012. Since then, we have identified the appropriate cases for the study and completed collection by laser captured microdissection (LCM) of all but two of the samples needed for genomic profiling. The collection of samples by LCM was an important part of the experiments in the first year of this project. Procedures for the collection of benign prostate tissues from patients free of CaP have been established. Internally funded collaborations have been established which will enhance the chances of success in this project by expanding the scope of genomic profiling. Two 2012 publications describe our findings related to the CaP field effect. Encouraged by these findings, we are actively pursuing the objectives of this project.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2012
- Accession Number
- ADA568098
Entities
People
- Farhad F. Kosari
- G. Vasmatzis
- J. C. Cheville
- M. Manemann
- R. J. Karnes
- S. J. Murphy
Organizations
- Mayo Clinic